



**University of Dundee**

## **A photodynamic therapy patient survey**

Ho, Bernard ; Howard, Natasha ; Howard, Sandra ; Cochrane, Andrea; Ferguson, John ; Ibbotson, Sally

*Published in:*  
Photodermatology, Photoimmunology & Photomedicine

*DOI:*  
[10.1111/phpp.12638](https://doi.org/10.1111/phpp.12638)

*Publication date:*  
2021

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Ho, B., Howard, N., Howard, S., Cochrane, A., Ferguson, J., & Ibbotson, S. (2021). A photodynamic therapy patient survey: real-life experience from two regional services. *Photodermatology, Photoimmunology & Photomedicine*, 37(3), 226-229. <https://doi.org/10.1111/phpp.12638>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



## A Photodynamic Therapy Patient Survey: real-life experience from two regional services

Journal:	<i>Photodermatology, Photoimmunology &amp; Photomedicine</i>
Manuscript ID	PHOTO-LE-04-20-0338.R1
Wiley - Manuscript type:	Letter to the Editor
Date Submitted by the Author:	19-Nov-2020
Complete List of Authors:	Ho, Bernard; St George's University Hospitals NHS Foundation Trust Howard, Natasha; Queen Mary Hospital Roehampton, Dermatology Howard, Sandra; Queen Mary Hospital Roehampton, Dermatology Cochrane, Andrea; St John's Institute Guys and St Thomas' NHS Foundation Trust, Photodermatology Unit Ferguson, John; St John's Institute Guys and St Thomas' NHS Foundation Trust , Photodermatology Unit Ibbotson, Sally; Ninewells Hospital Photobiology Unit
Keywords:	Photodynamic Therapy, Patient Survey, PDT

SCHOLARONE™  
Manuscripts

### **A Photodynamic Therapy Patient Survey: real-life experience from two regional services**

Bernard Ho<sup>1,2</sup>, Natasha Howard<sup>2</sup>, Sandra Howard<sup>2</sup>, Andrea Cochrane<sup>4</sup>, John Ferguson<sup>3</sup>, Sally Ibbotson<sup>4</sup>

<sup>1</sup>Dermatology Department, St George's University Hospitals NHS Foundation Trust, London, UK

<sup>2</sup>Dermatology Department, Queen Mary Hospital, Roehampton, UK

<sup>3</sup>Photodermatology Unit, St John's Institute, Guys and St Thomas' NHS Foundation Trust, London, UK

<sup>4</sup>Photobiology Unit, Ninewells Hospital & Medical School, School of Medicine, University of Dundee, UK

Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen's disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence-base regarding efficacy and high levels of patient satisfaction (1). The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices (2). Topical PDT involves application of a photosensitiser pro-drug (5-aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT) (1). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation (3). Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance (4, 5, 6).

Other treatment options include topical 5-fluorouracil (5-FU), imiquimod, ingenol mebutate (now discontinued), cryotherapy and surgery (1). Efficacy and adverse effects must be taken into account and patient and lesion characteristics, availability of services and patient choice typically influence treatment choice.

Historically, approximately 20% of patients reported severe pain with hospital-based PDT (3). However, our clinical impression was that over time as PDT services evolved, therapeutic tolerance has improved and pain rarely limits treatment delivery. Thus, we were keen to evaluate the real-life experience of patients receiving routine PDT in clinical practice outwith clinical trials, in two hospital settings. We evaluated this through a questionnaire-based approach.

The objectives of this survey were to evaluate the opinions of patients attending routine PDT clinics; specifically their views on PDT and other treatments received and to determine pain experienced during PDT. The questionnaires were developed by the authors and were in concordance with local hospital governance (Appendix: Supplementary information) and the survey was undertaken prospectively. Questionnaires were distributed in 2017 to patients attending one of two PDT clinics (Ninewells hospital (NWH), Dundee over 12 months and Queen Mary's Hospital (QMH), Roehampton, London over eight months), either immediately after PDT or during three-monthly follow-up. Completed questionnaires were returned at the end of the clinic visit, with 49% and 45% response rate at QMH and NWH respectively. Formal statistical analysis was not undertaken as numbers in subgroups were low and it was felt inappropriate to over-analyse data from this observational pilot survey.

A total of 155 patients (101 QMH; 55 NWH; 145 cPDT; 10 dPDT) completed the questionnaire. The demographics of patients were similar between centres, with an overall median age of 74 (range 36 - 92) years (Table 1). Overall, males and females were equally represented, although all 10 treated with

1  
2  
3 dPDT were male. Most patients received cPDT for BCC (33.8%) or BD (30.3%), whereas dPDT was used  
4 for AK (Table 1).  
5  
6

7 The majority of patients rated cPDT experience as “excellent” (67.6%) or good (22.8%), with similarly  
8 high ratings for dPDT (Table 1). Most cPDT patients experienced either mild (55.9%) or no (27.6%)  
9 pain, with similarly high tolerance levels rated for those who had dPDT (Table 1). Most patients  
10 experienced mild erythematous reactions, with only 11% of cPDT patients developing marked redness  
11 and most did not experience oedema or exudation. Information provided about treatment was  
12 deemed useful by 98.1% of patients and most were satisfied with cPDT (140, 96.6%) and dPDT (9,  
13 90%), with only a few who would not have cPDT (4, 2.8%) or dPDT (1, 10.0%) again (Table 1).  
14

15 One hundred and fifty patients (96%) were satisfied with PDT and 98% with the PDT information  
16 provided, with 79% being happy to have PDT again if required. Most patients (115; 74%) had received  
17 other treatments prior to PDT (Figure 1). Of the 30 who had received 5-FU, 25 (83%) described PDT as  
18 the superior treatment, with two preferring 5-FU and three reporting no difference. Of the 15 who  
19 had previously received Imiquimod, 12 (80%) preferred PDT, one preferred Imiquimod and two  
20 reported no preference. Of the four who had previously received ingenol mebutate, two preferred  
21 PDT and two described the treatments as similar, although ingenol mebutate is now no longer  
22 available. Of the 26 patients who had received cryotherapy, 15 (58%) preferred PDT, eight (31%)  
23 preferred cryotherapy and three (12%) reported no preference. Of the 70 patients who had surgery  
24 previously, 45 (64%) preferred PDT, 5 (7%) preferred surgery and 20 (29%) reported no preference.  
25 Reasons given for treatment preferences included convenience, effectiveness and adverse effects.  
26  
27  
28  
29  
30

31 Most patients (117; 74%) had received other treatments prior to PDT (Figure 1). Of the 30 patients  
32 who had received 5-FU, 23 (82.1%) and 2 (100%) considered cPDT and dPDT respectively to be  
33 superior. Of the 15 cPDT patients who had previously received imiquimod, 12 (80.0%) preferred cPDT.  
34 Of the four who had previously received ingenol mebutate, two preferred PDT. Of the 24 patients who  
35 had received cryotherapy, 14 (58.3%) preferred cPDT and 7 (29.2%) preferred cryotherapy. Of the 70  
36 patients who had surgery previously, 44 (64.7%) preferred cPDT and 1 (50%) preferred dPDT (Figure  
37 1). Reasons given for treatment preferences included convenience, effectiveness and adverse effects.  
38  
39  
40

41 Study limitations included use of an unvalidated patient questionnaire. We did seek an informal  
42 opinion of a user-experience designer to ensure the questionnaire as patient-orientated by minimising  
43 use of medical jargon and to ensure succinctness to minimise respondent fatigue (4). The purpose of  
44 the survey was to capture real-life experience of PDT and our data are in keeping with published  
45 findings from other studies reporting on patient satisfaction with daylight PDT (4,5,6).  
46  
47  
48

49 In summary, we have shown that PDT in routine clinical practice, is well tolerated by the majority of  
50 patients, with high levels of satisfaction and most reporting either no or minimal pain and this is for  
51 both hospital-LED-based PDT as well as daylight PDT. Additionally, when compared with other  
52 commonly used treatments, most patients preferred PDT. These findings support the clinical utility of  
53 dermatological PDT services for patients with dysplasia and superficial non-melanoma skin cancer.  
54  
55

56  
57 References  
58  
59  
60

- 1  
2  
3 1. Wong TH, Morton CA, Collier N, Haylett A, Ibbotson S, McKenna KE, et al. British Association  
4 of Dermatologists and British Photodermatology Group guidelines for topical photodynamic  
5 therapy 2018. *Br J Dermatol*. 2019; 180: 730–9.
- 6  
7 2. Service Guidance and Standards for Photodynamic Therapy (PDT). British Association of  
8 Dermatologist; 2018. [http://www.bad.org.uk/shared/get-](http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=6252)  
9 [file.ashx?itemtype=document&id=6252](http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=6252)
- 10  
11 3. Ibbotson, S., Wong, T., Morton, C., Collier, N., Haylett, A., McKenna, K., Mallipeddi, R.,  
12 Moseley, H., Rhodes, L., Seukeran, D., Ward, K., Mohd Mustapa, M. and Exton, L. Adverse  
13 effects of topical photodynamic therapy: A consensus review and approach to management.  
14 *Br J Dermatol* 2019; 180: 715-29
- 15  
16 4. See JA., Gebauer K., Wu JK., Manoharan S., Kerrouche N., and Sullivan J. High patient  
17 satisfaction with daylight-activated methyl aminolevulinate cream in the treatment of  
18 multiple actinic keratoses: results of an observational study in Australia. *Dermatol*  
19 *Ther* 2017; 7: 525–33
- 20  
21 5. Fagnoli MC., Ibbotson SH., Hunger RE., *et al.* Patient and physician satisfaction in an  
22 observational study with methyl aminolevulinate daylight photodynamic therapy in the  
23 treatment of multiple actinic keratoses of the face and scalp in six European countries. *J Eur*  
24 *Acad Dermatol Venereol* 2018; 32: 757–62
- 25  
26 6. García-Malín AJ., Gracia-Cazaña T., Gilaberte Y. Self-expressed patient preferences for the  
27 treatment of actinic keratosis: results from a non-interventional study based on a real-life  
28 setting in Spain. *Euro J Dermatol*; 2018; 28: 113-115
- 29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Legends


Appendix: Supplementary information – Questionnaire used in the PDT survey

Table 1: Demographics, disease characteristics, adverse effects and PDT treatment rating


Figure 1: Patient experience with previously used therapies

For Review Only

Figure 1






**dPDT compared with other treatment modalities (n=10)**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	PHOTO-manuscript copy			
	cPDT		dPDT	
	n	%	n	%
<b>Sex</b>				
Male	57	39.3%	10	100.0%
Female	69	47.6%		
NR	19	13.1%		
<b>Median Age</b>	74		74	
<b>Range</b>	36-92		57-79	
<b>Mean Age</b>	74		70	
<b>Std Deviation</b>	12.6		11	
<b>Diagnosis</b>				
AK	17	11.8%	6	60.0%
Bowen's	44	30.3%		
sBCC	49	33.8%		
Multiple Diagnosis	10	6.9%		
Other	17	11.7%		
NR	8	5.5%	4	40.0%
<b>Treatment Rating</b>				
Excellent	98	67.6%	3	30.0%
Good	33	22.8%	3	30.0%
Fair	0	0.0%	1	10.0%
Poor	1	0.6%	0	0.0%
NR	13	9.0%	3	30.0%
<b>Pain Rating</b>				
No pain	40	27.6%	6	60.0%
Mild, annoying	81	55.9%	4	40.0%
Nagging, upsetting	15	10.3%	0	0.0%
Distressing, miserable	2	1.4%	0	0.0%
Intense, dreadful	5	3.4%	0	0.0%
Worst possible	1	0.7%	0	0.0%
NR	1	0.7%	0	0.0%
<b>Redness</b>				
Not red	6	4.0%	2	20.0%
Slightly pink /slightly red	47	32.0%	6	60.0%
Pink /Red	62	43.0%	0	0.0%
Very Red	16	11.0%	0	0.0%
NR	14	10.0%	2	20.0%
<b>Swelling</b>				
Yes	37	25.5%	0	0.0%
No	105	72.4%	8	80.0%
NR	3	2.1%	2	20.0%
<b>Weeping</b>				
Yes	30	20.7%	0	0.0%
No	109	75.2%	8	80.0%
NR	6	4.1%	2	20.0%
<b>Leaflets Useful</b>				
Yes	142	97.9%	10	100.0%
No	3	2.1%	0	0.0%
NR	0	0.0%	0	0.0%
<b>Satisfied?</b>				
Yes	140	96.6%	9	90.0%
No	0	0.0%	0	0.0%
NR	5	3.4%	1	10.0%
<b>Therapy Again?</b>				
Yes	117	80.7%	6	60.0%
No	4	2.8%	1	10.0%
NR	24	16.5%	3	30.0%



Photodynamic Therapy (PDT) Survey			Date:				
Age:		Sex: F / M	Diagnosis:				
Post Treatment <input type="checkbox"/>			Follow-up <input type="checkbox"/>				
Which treatment did you have?							
<input type="checkbox"/> Conventional PDT		<input type="checkbox"/> Daylight PDT		<input type="checkbox"/> Ambulatory PDT (Home-based)			
How do you rate the therapy overall?							
Excellent		Good		Fair		Poor	
Directly after therapy, rate the following:							
Pain:		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			
	No pain	Mild, annoying pain	Nagging, upsetting pain	Distressing, miserable pain	Intense, dreadful, horrible pain	Worst possible, unbearable pain	
Redness:	Not red at all	Slightly pink	Pink	Slightly red	Red	Very Red	
Swelling:	No			Yes			
Weeping:	No			Yes			
General questions about PDT session:							
How long did it take to travel to hospital? (including your wait for transport)							
How long did it take you to recover after therapy? <i>(for follow-up patients only)</i>							
Were the written leaflets useful and clear?			No		Yes		
Were you satisfied with your therapy?			No		Yes		
Will you have this therapy again?			No		Yes		

1					
2	1. Have you had any treatment before today for your lesions? Yes/No. (if "no" go to section 4)				
3	2. Compared to the treatment you had, how did this PDT treatment compare to the following?				
4					
5	3. 5FU (Efudix)	Does not apply to me	Worse than 5FU	Similar to 5FU	Better than 5FU
6	Why worse or better?				
7					
8					
9					
10					
11					
12					
13					
14					
15					
16	Imiquimod (Aldara)	Does not apply to me	Worse than imiquimod	Similar to imiquimod	Better than imiquimod
17	Why worse or better?				
18					
19					
20					
21					
22					
23					
24					
25					
26					
27					
28	Ingenol Mebutate (Picato)	Does not apply to me	Worse than Picato	Similar to Picato	Better than Picato
29	Why worse or better?				
30					
31					
32					
33					
34					
35					
36					
37					
38	PDT – <i>(please circle)</i> hospital-based/ ambulatory/Daylight PDT	Does not apply to me	Worse than previous PDT	Similar to previous PDT	Better than previous PDT
39	Why worse or better?				
40					
41					
42					
43					
44					
45					
46					
47					
48					
49					
50	Cryotherapy	Does not apply to me	Worse than cryotherapy	Similar to cryotherapy	Better than cryotherapy
51	Why worse or better?				
52					
53					
54					
55					
56					
57					
58					
59					
60					

1 2 3 4	Surgery (include cut out or scraped off)	Does not apply to me	Worse than surgery	Similar to surgery	Better than surgery
5 6 7 8 9 10	Why worse or better?				
11 12 13 14	Other: _____	Does not apply to me	Worse than this	Similar to this	Better than this
15 16 17 18 19 20 21 22	Why worse or better?				

23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	4. Is there anything else we should know? (i.e. general feedback, comfort, etc.)
--	--

### A Photodynamic Therapy Patient Survey: real-life experience from two regional services

Bernard Ho<sup>1,2</sup>, Natasha Howard<sup>2</sup>, Sandra Howard<sup>2</sup>, Andrea Cochrane<sup>4</sup>, John Ferguson<sup>3</sup>, Sally Ibbotson<sup>4</sup>

<sup>1</sup>Dermatology Department, St George's University Hospitals NHS Foundation Trust, London, UK

<sup>2</sup>Dermatology Department, Queen Mary Hospital, Roehampton, UK

<sup>3</sup>Photodermatology Unit, St John's Institute, Guys and St Thomas' NHS Foundation Trust, London, UK

<sup>4</sup>Photobiology Unit, Ninewells Hospital & Medical School, School of Medicine, University of Dundee, UK

Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen's disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence-base regarding efficacy and high levels of patient satisfaction (1). The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices ~~are in place~~ (2). Topical PDT involves application of a photosensitiser pro-drug (5-aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (~~conventional PDT; cPDT~~) (1). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation (3). Daylight PDT (~~dPDT~~) is also increasingly used for AK with high levels of tolerance (4, 5, 6).

Other treatment options include topical 5-fluorouracil (5-FU), imiquimod, ~~ingenol mebutate (now discontinued)~~, cryotherapy and surgery (1). Efficacy and adverse effects must be taken into account and patient and lesion characteristics, availability of services and patient choice typically influence treatment choice.

Historically, approximately 20% of patients reported severe pain with hospital-based PDT (3). However, our clinical impression was that over time as PDT services evolved, therapeutic tolerance has improved and pain rarely limits treatment delivery. Thus, we were keen to evaluate the real-life experience of patients receiving routine PDT in clinical practice outwith clinical trials, in two ~~separate~~ hospital settings. We evaluated this through a questionnaire-based approach.

The objectives of this survey were to evaluate the opinions of patients attending routine PDT clinics; specifically their views on PDT and other treatments received and to determine pain experienced during PDT.

The questionnaires were developed by the authors and were in concordance with local hospital governance (Appendix: Supplementary information) and the survey was undertaken prospectively. Questionnaires were distributed in 2017 to patients attending one of two PDT clinics (Ninewells hospital (NWH), Dundee over 12 months and Queen Mary's Hospital (QMH), Roehampton, London over eight months), either immediately after PDT or during three-monthly follow-up. Completed questionnaires were returned at the end of the clinic visit, with ~~49~~50% and 45% response rate at QMH and NWH respectively. Formal statistical analysis was not undertaken as numbers in subgroups were low and it was felt inappropriate to over-analyse data from this observational pilot survey.

A total of 1556 patients (101 QMH; 55 NWH; 145 cPDT; 10 dPDT) completed the questionnaire. The demographics of patients were similar between centres, with an overall median age of 74.2 (range 36 - 92) years (Table 1). ~~There was a slightly higher male to female ratio in QMH (1.3 : 1), although~~

1  
2  
3 overall, males and females were equally represented, although all 10 treated with dPDT were male.  
4 Most patients had received treatment cPDT for BCC (33.8%) or BD (30.3%) CC, whereas dPDT was  
5 used for AK with others having AK or a combination of AK, BD, BCC. Most patients received hospital-  
6 based LED PDT, although 10 received daylight PDT and these data are presented separately as are  
7 those for lesion type (Table 1).  
8  
9

10  
11 The majority of patients (102; 65%) rated the cPDT experience overall as "excellent" (67.6%)  
12 or good (and 22.83%), with similarly high ratings for dPDT (Table 1) as "good". Most cPDT patients  
13 experienced either mild (55.9%) or no (27.6%) pain, with similarly high tolerance levels rated for those  
14 who had dPDT (Table 1). Forty-seven patients (30%) reported that they experienced "no pain" and a  
15 further 85 patients (55%) reported "mild, annoying" pain; with the remaining 23 patients (15%)  
16 reporting more intense pain. Most patients experienced had mild erythematous reactions, with only 11%  
17 of cPDT patients developing marked redness but no oedema or exudation and most did not experience  
18 oedema or exudation. Information provided about treatment was deemed useful by 98.1% of patients  
19 and most were satisfied with cPDT (140, 96.6%) and dPDT (9, 90%), with only a few who would not  
20 have cPDT (4, 2.8%) or dPDT (1, 10.0%) again (Table 1).  
21  
22

23  
24 One hundred and fifty patients (96%) were satisfied with PDT and 98% with the PDT information  
25 provided, with 79% being happy to have PDT again if required. Most patients (115; 74%) had received  
26 other treatments prior to PDT (Figure 1). Of the 30 who had received 5-FU, 25 (83%) described PDT as  
27 the superior treatment, with two preferring 5-FU and three reporting no difference. Of the 15 who  
28 had previously received Imiquimod, 12 (80%) preferred PDT, one preferred Imiquimod and two  
29 reported no preference. Of the four who had previously received ingenol mebutate, two preferred  
30 PDT and two described the treatments as similar, although ingenol mebutate is now no longer  
31 available. Of the 26 patients who had received cryotherapy, 15 (58%) preferred PDT, eight (31%)  
32 preferred cryotherapy and three (12%) reported no preference. Of the 70 patients who had surgery  
33 previously, 45 (64%) preferred PDT, 5 (7%) preferred surgery and 20 (29%) reported no preference.  
34 Reasons given for treatment preferences included convenience, effectiveness and adverse effects.  
35  
36  
37  
38

39  
40 Most patients (117; 74%) had received other treatments prior to PDT (Figure 1). Of the 30 patients  
41 who had received 5-FU, 23 (82.1%) and 2 (100%) considered cPDT and dPDT respectively to be  
42 superior. Of the 15 cPDT patients who had previously received imiquimod, 12 (80.0%) preferred cPDT.  
43 Of the four who had previously received ingenol mebutate, two preferred PDT. Of the 24 patients who  
44 had received cryotherapy, 14 (58.3%) preferred cPDT and 7 (29.2%) preferred cryotherapy. Of the 70  
45 patients who had surgery previously, 44 (64.7%) preferred cPDT and 1 (50%) preferred dPDT (Figure  
46 1). Reasons given for treatment preferences included convenience, effectiveness and adverse effects.  
47  
48

49  
50 Study limitations included use of an unvalidated patient questionnaire. We did seek an informal  
51 opinion of a user-experience designer to ensure the questionnaire as patient-orientated by minimising  
52 use of medical jargon and to ensure succinctness to minimise respondent fatigue (4). The purpose of  
53 the survey was to capture real-life experience of PDT and our data are in keeping with published  
54 findings from other studies reporting on patient satisfaction with daylight PDT (4,5,6).  
55  
56

57  
58 In summary, we have shown that PDT in routine clinical practice, is well tolerated by the majority of  
59 patients, with high levels of satisfaction, and most with most reporting either no or minimal pain and  
60 this is for both hospital-LED-based PDT as well as daylight PDT. Additionally, when compared with

1  
2  
3 other commonly used treatments, most patients preferred PDT. These findings support the clinical  
4 utility of dermatological PDT services for patients with dysplasia and superficial non-melanoma skin  
5 cancer.  
6  
7

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

References:

1. Wong TH, Morton CA, Collier N, Haylett A, Ibbotson S, McKenna KE, et al. British Association of Dermatologists and British Photodermatology Group guidelines for topical photodynamic therapy 2018. *Br J Dermatol.* 2019; 180: 730–9.
2. Service Guidance and Standards for Photodynamic Therapy (PDT). British Association of Dermatologist; 2018. <http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=6252>
3. Ibbotson, S., Wong, T., Morton, C., Collier, N., Haylett, A., McKenna, K., Mallipeddi, R., Moseley, H., Rhodes, L., Seukeran, D., Ward, K., Mohd Mustapa, M. and Exton, L. Adverse effects of topical photodynamic therapy: A consensus review and approach to management. *Br J Dermatol* 2019; 180: 715-29
4. See JA., Gebauer K., Wu JK., Manoharan S., Kerrouche N., and Sullivan J. High patient satisfaction with daylight-activated methyl aminolevulinate cream in the treatment of multiple actinic keratoses: results of an observational study in Australia. *Dermatol Ther* 2017; 7: 525–33
5. Fagnoli MC., Ibbotson SH., Hunger RE., *et al.* Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. *J Eur Acad Dermatol Venereol* 2018; 32: 757–62
6. Ana Julia García-Malinis AJ., Tamara Gracia-Cazaña T., Yolanda Gilalaberte Y. Self-expressed patient preferences for the treatment of actinic keratosis: results from a non-interventional study based on a real-life setting in Spain. *Euro J Dermatol*; 2018; 28(4): 113-115

1  
2  
3  
4 Legends  
5  
6

7 Appendix: Supplementary information – Questionnaire used in the PDT survey  
8  
9

10 Table 1: Demographics, disease characteristics, adverse effect and PDT treatment rating  
11  
12

13 Figure 1: Patient experience with previously used therapies  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Review Only

1  
2  
3 November 2020  
4  
5

6 Professor Akimichi Morita  
7 Editor-in-Chief  
8 Professor and Chairman  
9 Department of Dermatology  
10 Nagoya City University,  
11 Nagoya  
12 Nagoya  
13 Japan  
14  
15

16 Dear Professor Morita  
17  
18

19 **Photodermatology Photoimmunology Photomedicine**  
20 **PHOTO-LE-04-20-0338**  
21

22 Thank you for the most helpful feedback from yourself, Professor Leone and the two reviewers and  
23 we welcome the opportunity to have improved on this manuscript in the light of this feedback. We  
24 have addressed all comments and hope that the revised manuscript is now suitable for publication in  
25 Photodermatology Photoimmunology Photomedicine. We detail below the point by point response  
26 to feedback and include a revised manuscript with changes included and highlighted, along with a  
27 clean version of this revised manuscript.  
28  
29

30 ***Associate Editors comments***

31 *As indicated in the points below, we have included more details on methodology in paragraph 4,*  
32 *separated out the data in Table 1 to show conventional and daylight data separately and to highlight*  
33 *the different lesion types. We have also included in the text the questionnaire response rate at each*  
34 *of the two centres (Line 8 paragraph 4).*  
35  
36

37 ***Reviewer: 1***

38 *Thank you for the positive feedback. We have corrected the typographical error on page 2, line 3 of*  
39 *reference 3: change "approacvh" to "approach".*  
40  
41

42 ***Reviewer: 2***

- 43 **1. I recommend presenting the results separated by the type of lesion treated making statistical**  
44 **analysis. In addition, the comparison with other treatments should be performed depending**  
45 **on the type of lesion. Also, daylight PDT and conventional PDT should be considered separately.**  
46 **A table is needed to present all these results.**  
47

48 *We hope that revision to the text of paragraphs 5,6 and 7 and changes to Table 1 now addresses*  
49 *these points. In the last sentence of paragraph 4 we have now explained why formal statistical*  
50 *analysis was not undertaken in this small observational survey as we consider that over analysis*  
51 *of small subgroups could potentially be misleading.*  
52  
53

- 54 **2. It is true that there is not a validated questionnaire specifically designed to evaluate patient's**  
55 **preference/satisfaction with PDT. However, there are previous studies with similar aims that**  
56 **the author should have taken into account in order to compare their results (See JA, et al.**  
57 **Dermatol Ther 2017;7:525; Garcia-Malinis A, et al. Eur J Dermatol 2018;28:113-115; Fargnoli MC**  
58 **et al. J Eur Acad Dermatol Venereol 2018;32:757-762).**  
59  
60

*Thank you and we have now included and referred to these three additional references in last lines*  
*of paragraphs 1 and 8 and include as references 4,5,6.*



- 1  
2  
3 **3. The questionnaire used should be provided at least as supplementary material.**  
4

5 *The questionnaire is now submitted as supplementary material and referred to in line 4 of*  
6 *paragraph 4.*  
7

- 8  
9 **4. The methodology is quite poor. Please give the type of study, the period of time during the**  
10 **study was carried out, calculation of the sample size and the statistical analysis performed. If**  
11 **the questionnaire was done during the follow-up, what was the limit of time since the PDT was**  
12 **performed? I think it is important in order to consider memory bias.**  
13

14 *We have now included more methodological information in paragraph 4, which explains how this*  
15 *prospective observational survey was undertaken and the follow up interval.*  
16

- 17  
18 **5. 156 patients completed the questionnaire. How many patients were requested to fill it? This**  
19 **data will tell us the percentage of response.**  
20

21 *We have included the questionnaire response figures for each centre in line 8, paragraph 4.*  
22

- 23 **6. Besides the range of the age, it is useful either to give the standard deviation or the percentile**  
24 **25-75 distribution in order to have an idea of the age distribution of the sample. A table**  
25 **summarizing the characteristics of the sample including sex, disease treated, type of treatment,**  
26 **photosensitizer used (MAL or ALA), type of PDT.**  
27

28 *These data are now included in Table 1.*  
29

- 30  
31 **7. The authors did not compare their results with others previously published; although they are**  
32 **not exactly the same because these studies focus only in actinic keratoses, and some only in**  
33 **daylight (See JA, et al. Dermatol Ther 2017;7:525; Garcia-Malinis A, et al. Eur J Dermatol**  
34 **2018;28:113-115; Fargnoli MC et al. J Eur Acad Dermatol Venereol 2018;32:757-762)**  
35

36 *Thank you and we have now included and referred to these three additional references in last lines*  
37 *of paragraphs 1 and 8 and include as references 4,5,6.*  
38

39  
40 We hope that with these revisions the manuscript is now suitable for publication in Photodermatology  
41 Photoimmunology Photomedicine and we look forward to hearing from you.  
42

43 Many thanks  
44

45 Kind regards  
46

47  
48  
49  
50 Bernard Ho  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60